Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom non-steroidal anti-inflammatory drugs (NSAIDs) and/ or colchicine are contraindicated, not tolerated, or ineffective. The efficacy of canakinumab was compared to the corticosteroid triamcinolone acetonide.
The purpose of the first 12 week extension study was to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2357.
The purpose of the second one year open-label extension study was to confirm the long-term safety and tolerability of canakinumab in patients who had completed the first extension study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Core Study:
Inclusion criteria:
Exclusion criteria:
Extension Study 1:
Inclusion:
Exclusion:
Extension Study 2:
Inclusion Criteria:
Exclusion Criteria:
-Continuation in this second extension study was considered inappropriate by the treating physician.
Other protocol-defined inclusion-exclusion criteria applied to the core and extension studies.
Primary purpose
Allocation
Interventional model
Masking
226 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal